Evaluation of Risk Factors Predicting Chemotherapy-Related Nausea and Vomiting: Results From a European Prospective Observational Study
- 26 September 2013
- journal article
- research article
- Published by Elsevier BV in Journal of Pain and Symptom Management
- Vol. 47 (5), 839-848.e4
- https://doi.org/10.1016/j.jpainsymman.2013.06.012
Abstract
No abstract availableKeywords
Funding Information
- Merck Sharp & Dohme Corp.
This publication has 20 references indexed in Scilit:
- Patient- and Treatment-Related Risk Factors for Nausea and Emesis during Concurrent ChemoradiotherapyStrahlentherapie und Onkologie, 2010
- Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational studySupportive Care in Cancer, 2010
- Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapySupportive Care in Cancer, 2010
- Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapySupportive Care in Cancer, 2009
- Clinical Predictors of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients Receiving Adjuvant Doxorubicin and CyclophosphamideAnnals of Pharmacotherapy, 2009
- Patient expectation is a strong predictor of severe nausea after chemotherapyCancer, 2004
- Biobehavioral factors in chemotherapy-induced nausea and vomiting.Journal of the National Comprehensive Cancer Network, 2004
- Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patientsSupportive Care in Cancer, 2002
- Patient expectations as predictor of chemotherapy-induced nauseaAnnals of Behavioral Medicine, 2000
- Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1997